VIGONVITA-B Posts Interim Results with Net Loss Narrowing 29.4% to RMB 122 Million

Stock News

Aug 28

VIGONVITA-B (02630) has released its interim results for the six months ended June 30, 2026, reporting a significant improvement in financial performance despite ongoing losses.

The company achieved revenue of RMB 132 million during the period, marking a substantial increase of 693.7% year-on-year. The net loss attributable to shareholders narrowed to RMB 122 million, reflecting a 29.4% reduction compared to the same period last year. Basic loss per share stood at RMB 0.73.

According to the company's announcement, the revenue surge was primarily driven by two key factors. Firstly, since July 2025, the group commenced the commercialization of a new pharmaceutical product, with sales volumes continuing to rise steadily, contributing an additional RMB 107 million to revenue. Secondly, in December 2025, the group formally entered into a licensing agreement with a client regarding new indications for VV116, and subsequently received milestone payments totaling RMB 20 million during the first half of 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/1169881564"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1169881564\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1169881564?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-28 18:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1169881564","market":"other","top_or_hot":-1,"title":"VIGONVITA-B Posts Interim Results with Net Loss Narrowing 29.4% to RMB 122 Million","media":"Stock News","content":"<p><b>VIGONVITA-B</b> (02630) has released its interim results for the six months ended June 30, 2026, reporting a significant improvement in financial performance despite ongoing losses.<br><br>The company achieved revenue of RMB 132 million during the period, marking a substantial increase of 693.7% year-on-year. The net loss attributable to shareholders narrowed to RMB 122 million, reflecting a 29.4% reduction compared to the same period last year. Basic loss per share stood at RMB 0.73.<br><br>According to the company's announcement, the revenue surge was primarily driven by two key factors. Firstly, since July 2025, the group commenced the commercialization of a new pharmaceutical product, with sales volumes continuing to rise steadily, contributing an additional RMB 107 million to revenue. Secondly, in December 2025, the group formally entered into a licensing agreement with a client regarding new indications for VV116, and subsequently received milestone payments totaling RMB 20 million during the first half of 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>VIGONVITA-B Posts Interim Results with Net Loss Narrowing 29.4% to RMB 122 Million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVIGONVITA-B Posts Interim Results with Net Loss Narrowing 29.4% to RMB 122 Million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-08-28 18:22</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>VIGONVITA-B</b> (02630) has released its interim results for the six months ended June 30, 2026, reporting a significant improvement in financial performance despite ongoing losses.<br><br>The company achieved revenue of RMB 132 million during the period, marking a substantial increase of 693.7% year-on-year. The net loss attributable to shareholders narrowed to RMB 122 million, reflecting a 29.4% reduction compared to the same period last year. Basic loss per share stood at RMB 0.73.<br><br>According to the company's announcement, the revenue surge was primarily driven by two key factors. Firstly, since July 2025, the group commenced the commercialization of a new pharmaceutical product, with sales volumes continuing to rise steadily, contributing an additional RMB 107 million to revenue. Secondly, in December 2025, the group formally entered into a licensing agreement with a client regarding new indications for VV116, and subsequently received milestone payments totaling RMB 20 million during the first half of 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02630","symbol_name":"旺山旺水-B","start_time":0,"source_url":"","article_id":"1169881564","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1169881564","pubTimestamp":1787912536,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"VIGONVITA-B (02630) has released its interim results for the six months ended June 30, 2026, reporting a significant improvement in financial performance despite ongoing losses.The company achieved...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02630":"旺山旺水-B","BK1191":"制药"},"translate_title":"VIGONVITA-B公布中期业绩，净亏损收窄29.4%至人民币1.22亿元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02630":1},"content_text":"VIGONVITA-B (02630) has released its interim results for the six months ended June 30, 2026, reporting a significant improvement in financial performance despite ongoing losses.The company achieved revenue of RMB 132 million during the period, marking a substantial increase of 693.7% year-on-year. The net loss attributable to shareholders narrowed to RMB 122 million, reflecting a 29.4% reduction compared to the same period last year. Basic loss per share stood at RMB 0.73.According to the company's announcement, the revenue surge was primarily driven by two key factors. Firstly, since July 2025, the group commenced the commercialization of a new pharmaceutical product, with sales volumes continuing to rise steadily, contributing an additional RMB 107 million to revenue. Secondly, in December 2025, the group formally entered into a licensing agreement with a client regarding new indications for VV116, and subsequently received milestone payments totaling RMB 20 million during the first half of 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}